These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37259125)

  • 1. Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis.
    Reyes LF; Garcia E; Ibáñez-Prada ED; Serrano-Mayorga CC; Fuentes YV; Rodríguez A; Moreno G; Bastidas A; Gómez J; Gonzalez A; Frei CR; Celi LA; Martin-Loeches I; Waterer G
    Crit Care; 2023 May; 27(1):212. PubMed ID: 37259125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of prior pulmonary tuberculosis in treatment outcomes of HCAP and CAP patients in intensive care units.
    Lin FM; Feng JY; Fang WF; Wu CL; Yu CJ; Lin MC; Ku SC; Chen CW; Tu CY; Yang KY
    J Microbiol Immunol Infect; 2019 Apr; 52(2):320-328. PubMed ID: 30245205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.
    Laserna E; Sibila O; Fernandez JF; Maselli DJ; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Chest; 2014 May; 145(5):1114-1120. PubMed ID: 24458223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
    J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrolides are associated with a better survival rate in patients hospitalized with community-acquired but not healthcare-associated pneumonia.
    McEvoy C; Micek ST; Reichley RM; Kan J; Hoban A; Hoffmann J; Shorr AF; Kollef MH
    Surg Infect (Larchmt); 2014 Jun; 15(3):283-9. PubMed ID: 24801126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A targeted likelihood estimation comparing cefepime and piperacillin/tazobactam in critically ill patients with community-acquired pneumonia (CAP).
    Serrano-Mayorga CC; Duque S; Ibáñez-Prada ED; Garcia-Gallo E; Arrieta MPR; Bastidas A; Rodríguez A; Martin-Loeches I; Reyes LF
    Sci Rep; 2024 Jun; 14(1):13392. PubMed ID: 38862579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
    Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
    Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.
    Mongardon N; Max A; Bouglé A; Pène F; Lemiale V; Charpentier J; Cariou A; Chiche JD; Bedos JP; Mira JP
    Crit Care; 2012 Aug; 16(4):R155. PubMed ID: 22894879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System.
    Hsu JL; Siroka AM; Smith MW; Holodniy M; Meduri GU
    Int J Infect Dis; 2011 Jun; 15(6):e382-7. PubMed ID: 21393043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
    Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
    Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
    Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
    BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.
    Restrepo MI; Mortensen EM; Waterer GW; Wunderink RG; Coalson JJ; Anzueto A
    Eur Respir J; 2009 Jan; 33(1):153-9. PubMed ID: 18768577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.